Botanix Pharmaceuticals Limited (BXPHF)
OTCMKTS · Delayed Price · Currency is USD
0.0883
0.00 (0.00%)
Feb 11, 2026, 9:30 AM EST

Botanix Pharmaceuticals Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Revenue
5.792.073.772.756.88
Other Revenue
----0.01
5.792.073.772.756.89
Revenue Growth (YoY)
179.74%-45.14%36.94%-60.00%-9.07%
Cost of Revenue
3.773.655.7310.296.57
Gross Profit
2.02-1.58-1.96-7.540.32
Selling, General & Admin
62.157.944.414.282.62
Other Operating Expenses
--1.130.890.41
Operating Expenses
84.9312.417.175.653.7
Operating Income
-82.91-13.99-9.13-13.19-3.38
Interest Expense
-5.37-0.01-0.08-0.04-0.06
Interest & Investment Income
1.880.080.070.040.1
Currency Exchange Gain (Loss)
0.010.06-0.010.02-0
Pretax Income
-86.4-13.87-9.15-13.17-3.33
Net Income
-86.4-13.87-9.15-13.17-3.33
Net Income to Common
-86.4-13.87-9.15-13.17-3.33
Shares Outstanding (Basic)
1,8451,5021,154973973
Shares Outstanding (Diluted)
1,8451,5021,154973973
Shares Change (YoY)
22.87%30.12%18.58%0.02%3.91%
EPS (Basic)
-0.05-0.01-0.01-0.01-0.00
EPS (Diluted)
-0.05-0.01-0.01-0.01-0.00
Free Cash Flow
-78.87-8.24-12.08-11.19-2.98
Free Cash Flow Per Share
-0.04-0.01-0.01-0.01-0.00
Gross Margin
34.85%-76.48%-51.83%-273.62%4.58%
Operating Margin
-1432.24%-676.11%-241.93%-478.66%-49.08%
Profit Margin
-1492.37%-670.20%-242.66%-478.10%-48.41%
Free Cash Flow Margin
-1362.39%-398.17%-320.27%-406.24%-43.21%
EBITDA
-80.65-13.92-9.11-13.17-3.36
EBITDA Margin
---241.38%--48.84%
D&A For EBITDA
2.260.070.020.020.02
EBIT
-82.91-13.99-9.13-13.19-3.38
EBIT Margin
---241.93%--49.08%
Revenue as Reported
---2.79-
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.